GLP-1 Drug Companies Race to Improve Patient Experience With Monthly Shots and Reduced Side Effects
Pharmaceutical companies including Pfizer and Amgen are developing next-generation GLP-1 medications designed to be taken once a month instead of weekly, aiming to reduce side effects and improve the patient experience as these weight loss and diabetes drugs surge in popularity.
Market Competition and Innovation Drive
Drug companies are racing to catch up to Eli Lilly and Novo Nordisk, seeking to require fewer shots or reduce side effects. Pfizer and Amgen are working on new GLP-1 shots designed to be taken once a month rather than weekly. The rapid expansion of GLP-1 receptor agonists has created significant commercial opportunity as these medications continue to gain adoption for both diabetes management and weight loss.
Current Treatment Landscape
New co-agonists and multiagonists are being used more often in place of the classic GLP-1 receptor agonist semaglutide. This shift reflects the industry's focus on developing more sophisticated formulations that address patient concerns about injection frequency and tolerability. The next generation of GLP-1 drugs aims to maintain or improve efficacy while minimizing the gastrointestinal side effects that some patients experience with current weekly formulations.
Clinical Benefits and Broader Health Impact
Diabetes care is evolving rapidly, with technological advances converging—amplified by AI and wearable devices—and reshaping diagnostics, prevention, and treatment across the board. The development of improved GLP-1 formulations represents a key part of this broader transformation in metabolic disease management, potentially enabling more patients to benefit from these therapeutic advances with better adherence and tolerance profiles.
Industry Strategy
With Eli Lilly and Novo Nordisk currently dominating the GLP-1 market, competitors are investing heavily in next-generation formulations to capture market share. Monthly dosing options could significantly improve patient convenience and potentially expand access to these medications among populations that prefer less frequent injections.